COVID-19 Vaccination Program Interim Operational Guidance InterimJurisdiction Operational Operations Guidance Centers for Disease Control and Prevention (CDC) October 29, 2020 Version 2.0 COVID-19 VACCINATION PROGRAM INTERIM PLAYBOOK FOR JURISDICTION OPERATIONS – October 29, 2020 Table of Contents Executive Summary ....................................................................................................................................................5 Section 1: Public Health Preparedness Planning ........................................................................................................6 Improvement Planning .......................................................................................................................................6 COVID-19 Vaccination Program Planning ...........................................................................................................6 Section 2: COVID-19 Organizational Structure and Partner Involvement ..................................................................8 Planning and Coordination Team (Internal) .......................................................................................................8 State-Local Coordination ....................................................................................................................................8 Tribal Nations and Tribal Communities ..............................................................................................................9 COVID-19 Vaccination Program Implementation Committee (Internal and External) .......................................9 Related Guidance and Reference Materials .................................................................................................... 10 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................................... 11 Phase 1: Potentially Limited COVID-19 Vaccine Doses Available .................................................................... 12 Phase 2: Large Number of Doses Available; Supply Likely to Meet Demand .................................................. 13 Phase 3: Likely Sufficient Supply ...................................................................................................................... 14 Related Guidance and Reference Materials .................................................................................................... 14 Section 4: Critical Populations ................................................................................................................................. 15 Identifying and Estimating Critical Populations ............................................................................................... 15 Estimating Population Groups for Initial COVID-19 Vaccine Distribution During Phase 1 .............................. 16 Describing and Locating Critical Populations ................................................................................................... 16 Related Guidance and Reference Materials .................................................................................................... 17 Section 5: COVID-19 Vaccination Provider Recruitment and Enrollment ............................................................... 19 Vaccination Provider Recruitment ................................................................................................................... 19 Vaccination Provider Enrollment ..................................................................................................................... 21 COVID-19 Vaccination Provider Training ......................................................................................................... 23 Role of Commercial and Federal Partners ....................................................................................................... 25 Federal Pharmacy Partnership for COVID-19 Vaccination in Long-Term Care Facilities ................................. 26 Federal Direct Allocation to Pharmacy Partners (Phase 2) .............................................................................. 26 Related Guidance and Reference Materials .................................................................................................... 26 Section 6: Understanding a Jurisdiction’s COVID-19 Vaccine Administration Capacity .......................................... 27 Related Guidance and Reference Materials .................................................................................................... 28 Section 7: COVID-19 Vaccine Allocation, Ordering, Distribution, and Inventory Management ............................. 29 2 | Page Version 2.0 COVID-19 VACCINATION PROGRAM INTERIM PLAYBOOK FOR JURISDICTION OPERATIONS – October 29, 2020 Allocation ......................................................................................................................................................... 29 Ordering ........................................................................................................................................................... 29 Distribution ...................................................................................................................................................... 30 Inventory Management ................................................................................................................................... 31 COVID-19 Vaccine Recovery ............................................................................................................................ 32 Section 8: COVID-19 Vaccine Storage and Handling ............................................................................................... 33 Satellite, Temporary, and Off-Site Clinic Storage and Handling Considerations ............................................. 33 Section 9: COVID-19 Vaccine Administration Documentation and Reporting ........................................................ 35 Section 10: COVID-19 Vaccination Second-Dose Reminders .................................................................................. 37 Section 11: COVID-19 Requirements for Immunization Information Systems or Other External Systems ............ 38 System Infrastructure ...................................................................................................................................... 39 COVID-19 Vaccination Provider Preparation ................................................................................................... 39 Data Management ........................................................................................................................................... 39 Ordering and Inventory ................................................................................................................................... 40 Related Guidance and Reference Materials .................................................................................................... 40 Section 12: COVID-19 Vaccination Program Communication ................................................................................. 42 COVID-19 Vaccination Communication Objectives ......................................................................................... 42 Key Audiences .................................................................................................................................................. 42 Broad Communication Planning Phases .......................................................................................................... 42 Communication Activities ................................................................................................................................ 43 Messaging Considerations ............................................................................................................................... 43 Communication Channels ................................................................................................................................ 44 Partners and Trusted Sources .......................................................................................................................... 44 Crisis and Risk Communication ........................................................................................................................ 44 Related Guidance and Reference Materials .................................................................................................... 45 Section 13: Regulatory Considerations for COVID-19 Vaccination ......................................................................... 46 Emergency Use Authorization Fact Sheets ...................................................................................................... 46 Vaccine Information Statements ..................................................................................................................... 46 Section 14: COVID-19 Vaccine Safety Monitoring ................................................................................................... 47 Vaccine Adverse Event Reporting System ....................................................................................................... 47 v-safe ................................................................................................................................................................ 47 Vaccine Safety Datalink ...................................................................................................................................